Author + information
- Received March 20, 2020
- Revision received June 22, 2020
- Accepted June 23, 2020
- Published online September 28, 2020.
- Raphaëlle Bourgeois, MSca,b,∗,
- Romain Devillers, MSca,c,∗,
- Nicolas Perrot, MSca,b,
- Audrey-Anne Després, BSca,b,
- Marie-Chloé Boulanger, PhDa,
- Patricia L. Mitchell, PhDa,
- Jakie Guertin, BSca,b,
- Patrick Couture, MDa,d,
- Michael B. Boffa, PhDe,
- Corey A. Scipione, PhDe,
- Philippe Pibarot, PhD, DVMa,b,
- Marlys L. Koschinsky, PhDe,
- Patrick Mathieu, MD, MSca,c and
- Benoit J. Arsenault, PhDa,b,∗ ()
- aCentre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, Canada
- bDepartment of Medicine, Faculty of Medicine, Université Laval, Québec, Canada
- cDepartment of Surgery, Faculty of Medicine, Université Laval, Québec, Canada
- dCentre de Recherche du CHU de Québec, Quebec, Canada
- eRobarts Research Institute, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada
- ↵∗Address for correspondence:
Dr. Benoit J. Arsenault, Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec–Université Laval, Y-3106, 2725 Chemin Ste-Foy, Québec (QC) G1V 4G5 Canada.
• Lipoprotein(a) is an important carrier of autotaxin and lysophosphatidic acid in the bloodstream.
• Autotaxin might physically interact with apolipoprotein(a).
• The plasma concentration of autotaxin transported by lipoprotein(a) may be an important predictor of calcific aortic valve stenosis.
Our objectives were to determine whether autotaxin (ATX) is transported by lipoprotein(a) [Lp(a)] in human plasma and if could be used as a biomarker of calcific aortic valve stenosis (CAVS). We first found that ATX activity was higher in Lp(a) compared to low-density lipoprotein fractions in isolated fractions of 10 healthy participants. We developed a specific assay to measure ATX-Lp(a) in 88 patients with CAVS and 144 controls without CAVS. In a multivariable model corrected for CAVS risk factors, ATX-Lp(a) was associated with CAVS (p = 0.003). We concluded that ATX is preferentially transported by Lp(a) and might represent a novel biomarker for CAVS.
↵∗ Drs. Bourgeois and Devillers contributed equally to this work and are joint first authors.
This work was supported by the Canadian Institutes of Health Research (FRN155226 and FRN149068). Dr. Arsenault holds a junior scholar award from the Fonds de recherche du Québec: Santé (FRQS). Ms. Després is supported by a master’s training award from the FRQS. Dr. Mathieu holds a FRQS Research Chair on the Pathobiology of Calcific Aortic Valve Disease. Dr. Koschinsky is supported by a grant from the Heart and Stroke Foundation of Canada (G-17-0018740) for this work. Dr. Arsenault is a consultant for Novartis; and holds/has held research grants from Pfizer, and Ionis Pharmaceuticals. Dr. Mathieu is a consultant for Casebia Therapeutics. Dr. Koschinsky holds/has held research grants from Pfizer; is a member of advisory boards for Sanofi and Amgen; has received speaker honoraria/consulting fees from Amgen, Regeneron, and Eli Lilly; and holds/has held research contracts with Sanofi, Ionis, Eli Lilly, and Cardiovax.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received March 20, 2020.
- Revision received June 22, 2020.
- Accepted June 23, 2020.
- 2020 The Authors